OIS@SECO

MARCH 4, 2020 | ATLANTA, GA

The “Ophthalmic” Innovation Summit was introduced to facilitate meaningful interactions between ODs, MDs and Industry leaders to accelerate the adoption of innovative non-surgical therapies to address prevalent eye diseases and disorders.

OIS ISRAEL 2020

MARCH 18, 2020 | TEL AVIV, ISRAEL

Ophthalmology Innovation Summit is proud to announce our first international meeting in the beautiful city of Tel Aviv, Israel.

 

OIS ANTERIOR SEGMENT 2020

MAY 14, 2020 | CAMBRIDGE, MA

This Ophthalmology Innovation Summit unites over 600 Corporate, Clinical and Capital leaders to collaborate on the development and commercialization of innovative therapies for the anterior segment.

OIS RETINA 2020

JULY 23, 2020 | SEATTLE, WA

This Ophthalmology Innovation Summit unites 300 Corporate, Clinical and Capital leaders to collaborate on the development and commercialization of innovative therapies for the posterior segment.

12TH ANNUAL OIS 2020

NOVEMBER 12, 2020 | LAS VEGAS, NV

The Ophthalmology Innovation Summit began in 2009 and now unites over 1,200 Corporate, Clinical and Capital leaders to collaborate on the development and commercialization of innovative drugs, devices and diagnostics to address unmet vision disorders.

The Ophthalmology Innovation Summits facilitate meaningful interactions and the exchange of information between clinical, capital and corporate leaders to accelerate the development and commercialization of novel therapies to address unmet needs.

LATEST NEWS

Keeping an "Eye on Innovation" Through News & Analysis

Glaucoma 360: Promising data as the industry considers value

Glaucoma 360: Promising data as the industry considers value

“Innovation remains the largest driver of healthcare cost increase,” said David Parke II, MD, American Academy of Ophthalmology CEO, during the Glaucoma Research Foundation’s (GRF) ...
Ranibizumab More Cost-Effective Than PRP

Ranibizumab More Cost-Effective Than PRP

The use of ranibizumab 0.5 mg for proliferative diabetic retinopathy (PDR) compared with panretinal photocoagulation (PRP) appeared to be more cost effective for patients with ...
AbbVie and Allergan Are Going to Be Just Fine

AbbVie and Allergan Are Going to Be Just Fine

Media coverage of AbbVie’s (NYSE: ABBV) acquisition of Allergan (NYSE: AGN) in June was both bullish and bearish. In our initial coverage, we took a ...
Soft CL slows myopia in children

Soft CL slows myopia in children

Globally, the myopia market may be worth upwards of $28 billion by 2026, with single prescription corrective lenses holding a significant market share, according to ...
Lucentis and Eylea patent expirations in the micro-crystal ball

Lucentis and Eylea patent expirations in the micro-crystal ball

Over the past 10 years, the Dow Jones Industrial Average has seen a 10-year climb with small calendar-year dips seen in 2015 (-2.23%) and 2018 ...
OIS Index Posts a Strong Finish to 2019

OIS Index Posts a Strong Finish to 2019

The OIS Index of ophthalmic stocks made a strong comeback in Q4-2019, following a rough Q3. The index gained 16.2% in Q4, slightly underperforming the ...

STAY UP TO DATE WITH OIS

Get the Latest News, Podcasts and Videos.